NASDAQ$INO

Inovio Pharmaceuticals Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

INO reported Q4 2025, revenue of $65K, net income of $3.8M, diluted EPS of $0.06.

For Q4 2025, INO reported revenue of $65K, net income of $3.8M, diluted EPS was $0.06. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.

  • Revenue $65K.
  • Net income $3.8M.
  • Diluted EPS $0.06.

Headline financials

Total Revenue

$65.3K

Previous: $117K-44.2%
EPS (adj)

$0.06

Previous: -$0.65+109.2%
Net Income

$3.8M

Previous: -$25M+115.2%

Revenue & EPS history

Inovio · Revenue · Quarterly

$65.3K

Q4 2025-44.2%vs Q4 2024
Beat estimate in 6 of 14 quarters(43%)
ActualEstimate

Forward guidance

The quarterly filing discusses operating priorities, capital returns, and sector risks; numeric multi-quarter bridges vary by issuer.

Tailwinds

  • MD&A highlights liquidity, capital, and core business trends.
  • Segment or product commentary supports the earnings narrative.

Headwinds

  • Macro, rates, or input costs may pressure near-term margins.
  • One-time items can affect year-over-year comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

-1.6%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-5.9%

Avg return

30 days after

39%

25 / 64 earnings

Positive

+21.6%

Q4 2014

Best reaction

-27.8%

Q2 2013

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.3%-13.5%-22.0%
Q4 2025-1.2%-1.2%-36.9%
Q3 2025-7.1%-4.7%-0.9%
Q1 2025-1.6%+7.8%+4.2%
Q4 2024-6.7%-10.5%-17.1%
Q3 2024-13.9%-18.6%-53.1%
Q2 2024-1.7%-8.1%-26.9%
Q1 2024+7.2%+12.7%-11.0%
Q4 2023-6.7%+24.4%+21.9%
Q3 2023-7.9%+0.0%+0.0%
Q2 2023+9.5%+9.5%+7.1%
Q1 2023-7.1%-8.3%-38.1%
Q4 2022+3.2%-4.0%-34.9%
Q3 2022+1.4%+9.3%-14.4%
Q2 2022+10.2%+11.4%-8.5%
Q1 2022-23.6%-16.0%-30.4%
Q4 2021-5.9%-4.0%+10.8%
Q3 2021+5.6%+9.1%-7.0%
Q2 2021-5.9%+1.3%-9.2%
Q1 2021-5.3%-4.4%+46.4%
Q4 2020-9.7%-17.2%-16.4%
Q3 2020+9.3%+6.6%+8.5%
Q2 2020-27.7%-26.9%-49.2%
Q1 2020+18.8%+23.7%+23.3%
Q4 2019-14.0%-12.3%-3.0%
Q3 2019-5.7%-4.1%+10.6%
Q2 2019-1.6%-6.3%-15.8%
Q1 2019-4.4%-9.2%-37.2%
Q4 2018+3.7%+0.0%+15.9%
Q3 2018+1.1%-7.5%-1.3%
Q2 2018+14.3%+13.8%+35.5%
Q1 2018-6.2%+1.1%-5.1%
Q4 2017+6.6%+12.6%+11.5%
Q3 2017-16.6%-14.3%-15.3%
Q2 2017-0.2%-1.4%+7.8%
Q1 2017+5.8%+15.2%+27.0%
Q4 2016-6.1%-7.7%-7.9%
Q3 2016+18.7%+26.8%+8.7%
Q2 2016-8.1%-9.1%-8.1%
Q1 2016+4.7%
Q4 2015-4.9%
Q3 2015+3.1%
Q2 2015+20.5%
Q1 2015+1.1%
Q4 2014+21.6%
Q3 2014+0.6%
Q2 2014-12.9%
Q1 2014+2.8%
Q4 2013-2.0%
Q3 2013-1.1%
Q2 2013-27.8%
Q1 2013+1.6%
Q4 2012-1.9%
Q3 2012-7.6%
Q2 2012+1.9%
Q1 2012-2.0%
Q4 2011-6.5%
Q3 2011-4.8%
Q2 2011+1.7%
Q1 2011+0.0%
Q4 2010-1.8%
Q3 2010+5.9%
Q2 2010-1.1%
Q1 2010-7.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro